Update on the Etiology and Treatment of Schizophrenia and Bipolar Disorder

CNS Spectrums

Volumn 13, Issue S1, 2008, Pages 1-12

  Buckley, Peter F ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; NEUROLEPTIC AGENT; TRANQUILIZER;

BIPOLAR DISORDER; CLINICAL TRIAL; COMORBIDITY; CROSS-SECTIONAL STUDY; HUMAN; INCIDENCE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PATIENT CARE; PSYCHOLOGICAL RATING SCALE; REVIEW; SCHIZOPHRENIA; STATISTICS; SUICIDE;

ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; COMORBIDITY; CROSS-SECTIONAL STUDIES; HUMANS; INCIDENCE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT CARE TEAM; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SUICIDE;

EID: 42949117276     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900028212     Document Type: Article

References (77)

1. Murray, CJL, Lopez, AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. 1st ed. Cambridge: Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1996.
2. Baldessarini, RJ, Pompili, M, Tondo, L. Suicide in bipolar disorder: risks and management. CNS Spectr. 2006; 11(6):465–471.
3. Goodwin, FK, Jamison, KR. Manic-Depressive Illness. New York, NY: Oxford University Press; 1990.
4. Jamison, KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000; 61(suppl 9):47–51.
5. Dalton, EJ, Cate-Carter, TD, Mundo, E, Parikh, SV, Kennedy, JL. Suicide risk in bipolar patients: the role of co-morbid substance use disorders. Bipolar Disord. 2003; 5(1):58–61.
6. Hawton, K, Sutton, L, Haw, C, et al. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry. 2005; 66(6):693–704.
7. Palmer, BA, Pankratz, VS, Bostwick, JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005; 62(3):247–253.
8. Buckley, P. Considerations of Medical Comorbidity in Schizophrenia. Available at: www.medscape.com/infosite/schizophrenia-)management/article-4. Accessed December 18, 2007.
9. Newcomer, JW. Medical risk in patients with bipolar disorder and schizophrenia. J Clin Psychiatry. 2006; 67(suppl 9):25–30.
10. Krishnan, KR. Psychiatric and medical comorbidities of bipolar disorder. Psychosom Med. 2005; 67(1):1–8.
11. Regier, DA, Farmer, ME, Rae, DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990; 264(19):2511–2518.
12. Caspi, A, Moffitt, TE, Cannon, M, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry. 2005; 57(10):1117–1127.
13. Merikangas, KR, Akiskal, HS, Angst, J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007; 64(5):543–552.
14. Kessler, RC, Chiu, WT, Demler, O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatry. 2005; 62(6):617–627.
15. Regier, DA, Narrow, WE, Rae, DS, et al. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993; 50(2):85–94.
16. Celten, JP, Sijben, N. First admission rates for schizophrenia in immigrants to the Netherlands: The Dutch National Register. Soc Psychiatry Psychiatr Epidemiol. 1994; 29(2):71–77.
17. Grove, W, Clayton, PJ, Endicott, J, et al. Immigration and major affective disorder. Acta Psychiatr Scand. 1986; 74(6):548–552.
18. Kendler, KS. Twin studies of psychiatric illness. Current status and future directions. Arch Gen Psychiatry. 1993; 50(11):905–915.
19. Kendler, KS. Genetic epidemiology in psychiatry. Taking both genes and environment seriously. Arch Gen Psychiatry. 1995; 52(11):895–899.
20. Craddock, N, O'Donovan, MC, Owen, MJ. The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet. 2005; 42(3):193–204.
21. Cannon, M, Jones, PB, Murray, RM. Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatry. 2002; 159(7):1080–1092.
22. O'Callaghan, E, Gibson, T, Colohan, HA, et al. Season of birth in schizophrenia. Evidence for confinement of an excess of winter births to patients without a family history of mental disorder. Br J Psychiatry. 1991; 158: 764–769.
23. Cammit, S, Allebeck, P, Dalman, C. Paternal age and risk for schizophrenia. Br J Psychiatry. 2003; 183: 405–408.
24. Gorwood, P, Leboyer, M, Jay, M, et al. Gender and age at onset in schizophrenia: impact of family history. Am J Psychiatry. 1995; 152(2):208–212.
25. Correll, CU, Penzner, JB, Frederickson, AM, et al. Differentiation in the preonset phases of schizophrenia and mood disorders: evidence in support of a bipolar mania prodrome. Schizophr Bull. 2007; 33(3):703–714.
26. Cddington, J. The diagnosis and assessment of individuals prodromal for schizophrenia psychosis. CNS Spectr. 2004; 9(8):588–594.
27. Peralta, V, Cuesta, MJ, Martinez-Larrea, A, et al. Duration of untreated psychotic illness: the role of premorbid social support networks. Soc Psychiatry Psychiatr Epidemiol. 2005; 40(5):345–349.
28. Kapur, S, Mamo, D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 1081–1090.
29. Scott, JE, Dixon, LB. Psychological interventions for schizophrenia. Schizophr Bull. 1995; 21(4):621–630.
30. Dixon, LB, Lehman, AF. Family interventions for schizophrenia. Schizophr Bull. 1995; 21(4):631–643.
31. National Alliance on Mental Illness. About Mental Illness. Available at: www.nami.org/Template.cfm?Section=By_Illness&Template=/TaggedPage/TaggedPageDisplay.cfm&TPLID=54&ContentID=23037. Accessed on December 18, 2007.
32. McGurk, SR. Neurocognition as a determinant of employment status in schizophrenia. J Psychiatr Pract. 2000; 6(1):190–196.
33. Davis, LW, Lysaker, PH. Therapeutic alliance and improvements in work performance over time in patients with schizophrenia. J Nerv Ment Dis. 2007; 195(4):353–357.
34. Lehman, AF. Vocational rehabilitation in schizophrenia. Schizophr Bull. 1995; 21(4):645–656.
35. Killackey, EJ, Jackson, HJ, Gleeson, J, Hickie, IB, McGorry, PD. Exciting career opportunity beckons! Early intervention and vocational rehabilitation in first-episode psychosis: employing cautious optimism. Aust N Z J Psychiatry. 2006; 40(11-12):951–962.
36. Liu, KW, Hollis, V, Warren, S, Williamson, DL. Supported-employment program processes and outcomes: experiences of people with schizophrenia. Am J Occup Ther. 2007; 61(5):543–554.
37. Principles of the ACT Model. Available at: www.actassociation.org/actModel. Accessed on December 18, 2007.
38. Phillips, SD, Burns, BJ, Edgar, ER, et al. Moving assertive community treatment into standard practice. Psychiatr Serv. 2001; 52(6):771–779.
39. Holthausen, EA, Wiersma, D, Cahn, W, et al. Predictive value of cognition for different domains of outcome in recent-onset schizophrenia. Psychiatry Res. 2007; 149(1-3):71–80.
40. Bell, M, Fiszdon, J, Greig, T, Wexler, B, Bryson, G. Neurocognitive enhancement therapy with work therapy in schizophrenia: 6-month follow-up of neuropsychological performance. J Rehabil Res Dev. 2007; 44(5):761–770.
41. Granholm, E, McQuaid, JR, McClure, FS, et al. Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up. J Clin Psychiatry. 2007; 68(5):730–737.
42. Levin, ED, Rezvani, AH. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function. Biochem Pharmacol. 2007; 74(8):1182–1191.
43. Prochaska, JJ, Hall, SM, Bero, LA. Tobacco Use Among Individuals With Schizophrenia: What Role Has the Tobacco Industry Played? Schizophr Bull. 2007. In press.
44. Goldberg, TE, Goldman, RS, Burdick, KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007; 64(10):1115–1122.
45. Stys, PK, Lipton, SA. White matter NMDA receptors: an unexpected new therapeutic target? Trends Pharmacol Sci. 2007; 28(11):561–566.
46. Robbins, MJ, Starr, KR, Honey, A, et al. Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. Brain Res. 2007; 1152: 215–227.
47. Castner, SA, Williams, GV. Tuning the engine of cognition: a focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn. 2007; 63(2):94–122.
48. Buchanan, RW, Davis, M, Goff, D, et al. A summary of the FD A-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005; 31(1):5–19.
49. Manschreck, TC, Boshes, RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry. 2007; 15(5):245–258.
50. Glick, ID. Understanding the results of CATIE in the context of the field. CNS Spectr. 2006; 11(suppl 7):40–47.
51. Moore, TA, Buchanan, RW, Buckley, PF, et al. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007; 68: 1751–1762.
52. Kucukalic, A, Dzubur-Kulenovic, A, Mehmedika-Suljic, E. Relapse prevention in schizophrenia - new therapeutic challenges. Psychiatr Danub. 2007; 19(4):362–366.
53. Perkins, DO, Johnson, JL, Hamer, RM, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res. 2006; 83(1):53–63.
54. Lacro, JP, Dunn, LB, Dolder, CR, Leckband, SG, Jeste, DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002; 63(10):892–909.
55. Buckley, PF, Wirshing, DA, Pierre, J, Bushen, P, Resnick, S, Wishing, SC. Lack of insight and treatment adherence in schizophrenia. CNS Drugs. 2007; 21: 129–141.
56. Valenstein, M, Ganoczy, D, McCarthy, JF, Myra Kim, H, Lee, TA, Blow, FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006; 67(10):1542–1550.
57. Tunis, SL, Faries, DE, Stensland, MD, Hay, DP, Kinon, BJ. An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia. Curr Med Res Opin. 2007; 23(1):97–104.
58. Tandon, R, Carpenter, WT, Davis, JM. First- and second-generation antipsychotics: learning from CUtLASS and CATIE. Arch Gen Psychiatry. 2007; 64(8):977–978.
59. Egan, MF, Straub, RE, Goldberg, TE, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A. 2004; 101(34):12604–12609.
60. Harrison, PJ, Weinberger, DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005; 10: 40–68.
61. Laruelle, M, Frankle, WG, Narendran, R, Kegeles, LS, Abi-Dargham, A. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation. Clin Ther. 2005; 27(suppl A):S16–S24.
62. Huxley, NA, Parikh, SV, Baldessarini, RJ. Effectiveness of psychosocial treatments in bipolar disorder: state of the evidence. Harv Rev Psychiatry. 2000; 8(3):126–140.
63. Fountoulakis, KN, Vieta, E, Siamouli, M, et al. Treatment of bipolar disorder: a complex treatment for a multi-facet disorder. Ann Gen Psychiatry. 2007; 6(1):27.
64. Sachs, GS, Thase, ME. Bipolar disorder therapeutics: maintenance treatment. Biol Psychiatry. 2000; 48(6):573–581.
65. Perlis, R. Review: adding second generation antipsychotics to mood stabilizers reduces acute mania symptoms. Evid Based Ment Health. 2007; 10: 111.
66. Surja, AA, Tamas, RL, El-Mallakh, RS. Antipsychotic medications in the treatment of bipolar disorder. Curr Drug Targets. 2006; 1217–1224.
67. Miklowitz, DJ, Otto, MW, Frank, E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry. 2007; 64(4):419–426.
68. Depression Bipolar Support Alliance. Available at: www.dbsalliance.org. Accessed on January 18, 2008.
69. Justo, L, Soares, B, Calil, H. Family interventions for bipolar disorder. Cochrane Database Syst Rev. 2007;(4):CD005167.
70. Amann, B, Grunze, H, Vieta, E, Trimble, M. Antiepileptic drugs and mood stability. Clin EEG Neurosci. 2007; 38(2):116–123.
71. Perlis, RH, Ostacher, MJ, Patel, JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am J Psychiatry. 2006; 163(2):217–224.
72. Lieberman, JA, Stroup, TS, McEvoy, JP, et al, and the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209–1223.
73. Zaremba, PD, Bialek, M, Blaszczyk, B, Cioczek, P, Czuczwar, SJ. Non-epilepsy uses of antiepilepsy drugs. Pharmacol Rep. 2006; 58(1):1–12.
74. Chiu, CC, Huang, SY, Chen, CC, Su, KP. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry. 2005; 66(12):1613–1614.
75. Yurgelun-Todd, DA, Silveri, MM, Gruber, SA, Rohan, ML, Pimentel, PJ. White matter abnormalities observed in bipolar disorder: a diffusion tensor imaging study. Bipolar Disord. 2007; 9(5):504–512.
76. Shaltiel, G, Chen, G, Manji, HK. Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. Curr Opin Pharmacol. 2007; 7(1):22–26.
77. Buckley, PF, Mahadik, S, Pillai, A, Terry, A Jr. Neurotrophins and schizophrenia. Schizophr Res. 2007; 94(1-3):1–11.